Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia [TheStreet.com]
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences (NBIX) had its price target raised by Leerink Partners from $160.00 to $170.00. They now have an "outperform" rating on the stock.
Neurocrine Biosciences (NBIX) was upgraded by Zacks Research from "strong sell" to "hold".
How Investors May Respond To Neurocrine Biosciences (NBIX) INGREZZA Real-World Persistence Edge Over AUSTEDO XR [Yahoo! Finance]